| Date | Title | Description |
| 09.09.2026 | Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer | Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies currently exist
SYDNEY, Sept. 9, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ... |
| 28.08.2026 | Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer | Durable Complete Metabolic Response Ongoing Since November 2025
All Evaluable Patients Demonstrated Reductions in Metastasis-Associated CTC Clusters and Terminally Exhausted T cells, With Median Reductions of 83% and 51% Respectively
No Tre... |
| 28.08.2026 | Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering | SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restor... |
| 28.08.2026 | Kazia Therapeutics Limited Announces Proposed Public Offering | SYDNEY, Aug. 28, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restor... |
| 11.06.2026 | Peer-reviewed publication shows that Lateral pharma's SCP drugs for neuropathic pain act via the novel target LanCL1 | MELBOURNE, Australia, June 11, 2026 /PRNewswire/ -- Lateral Pharma today announced the publication of peer-reviewed research in PAIN, a leading journal dedicated to pain research, identifying Lanthionine Synthetase C-Like Protein 1 (LanCL1)... |
| 26.05.2026 | Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer | Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability Data
SYDNEY, May 26, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company")... |
| 24.04.2026 | Kurma Partners: €215 Million Biofund IV Closes As Total AUM Reach €1 Billion | Kurma Partners, a Paris-based European healthcare venture capital firm and Eurazeo group company, has announced the final closing of Biofund IV at €215 million, bringing total assets under management across all Kurma Partners franchises to ... |
| 19.03.2026 | How Can You Benefit from Gas Turbine Electric Generators? | Share
Share
Share
Share
Email
A robust and cost-effective energy supply is essential for industrial, commercial, and marine industries. From keeping vital operations running offshore to powering massive manufacturing plants, reliable electr... |
| 10.03.2026 | Cellbox Solutions Secures €3.5M to Revolutionize Global Live Cell Transport | Cellbox Solutions, a German innovator, just secured €3.5 million in Series A funding. This investment accelerates the global reach of its patented warm-chain logistics. Their portable CO2 incubators ensure safe, controlled transport of livi... |
| 09.03.2026 | Cellbox Solutions: €3.5 Million Raised For Warm-Chain Technology To Transport Living Cells | Germany-based Cellbox Solutions has raised approximately €3.5 million in the first closing of its Series A financing round to accelerate global expansion of its warm-chain logistics technology for transporting living cells under controlled ... |
| 24.02.2026 | Centauri Therapeutics extends Series A to £30M with £6M investment from AMR Action Fund to support progression of lead clinical candidate | Clinical candidate in ABX-01 programme, CTX-187, currently in development ahead of first in-human clinical trials to target Gram-negative bacterial infections
Investment from the world’s largest venture capital fund focused exclusively on a... |
| 24.02.2026 | Centauri Therapeutics: £6 Million Raised For Advancing Antimicrobial Candidate | Centauri Therapeutics Limited, an immunotherapy company developing novel treatments for infectious diseases, has secured £6 million from AMR Action Fund, extending its Series A financing to £30 million. The funding will support completion o... |
| 27.01.2026 | Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer | SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (S... |
| 10.12.2025 | Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including... | First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions in circulating tumor cells (CTC) and clusters
Reinvigoration of immune system + turning cold tumors hot
Preliminary ex-vivo data in HER2+ pa... |
| 27.10.2025 | Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner | SYDNEY, Oct. 27, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") today announced its intention to request and hold a follow-up Type C meeting with the U.S. Food & Drug Administration (FDA) ... |
| 07.10.2025 | Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program | SYDNEY, Oct. 7, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced an exclusive collaboration and in-licensing agreement (the "Agreement") with QIMR Bergho... |
| 11.09.2025 | Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy | SYDNEY, Sept. 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program led by Professor Sudha Rao at QIMR Berghofer.... |
| 09.07.2025 | Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase ... | SYDNEY, July 9, 2025 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, pembrolizumab (Keytruda®), and sta... |
| 23.05.2025 | Fortaco sells its marine business in Gruza, Serbia | Fortaco sells its marine business in Gruza, Serbia
Fri, May 23, 2025 15:00 CET Report this content
Fortaco Group Holdco Plc. | PRESS RELEASE 23.5.2025 at 16.00 EEST
Fortaco Group Holdco Plc’s subsidiary, Fortaco Oy has signed an agreement t... |
| 24.02.2025 | Europe markets close lower as German stocks cling to post-election gains; Just Eat shares surge 54% | European markets fell on Monday as traders reacted to the results of the German federal election.
The pan-European Stoxx 600 index closed 0.08% lower, weighed down by France’s CAC 40 index, as Germany’s DAX gave up some of its earlier gains... |
| 19.02.2025 | Advancing Data Centric AI in Healthcare and Life Sciences – Elucidata Onboards Former CEO of Evotec and Ex-McKinsey Senior Partner | Elucidata, the leading data-centric AI solutions and technology company, is proud to welcome Dr. Werner Lanthaler and Dr. Navjot Singh to its leadership team as Independent Board Member and Advisor, respectively. Recognized as the Most Inno... |
| 15.11.2024 | Biomarkers of Aging Consortium Announces Winners of Prestigious Biomarkers of Aging Challenge | 2024 Biomarkers of Aging Conference at Harvard
The Biomarkers of Aging Consortium has announced the winners of the 2024 Biomarkers of Aging Challenge Series, recognizing significant advances in predicting biological age and mortality risk t... |
| 10.09.2024 | NanoSyrinx: A New Dawn in Biotech with £10 Million Funding | In the world of biotechnology, innovation is the lifeblood. Today, a new player is making waves. NanoSyrinx, a synthetic biology company based in Coventry, UK, has successfully raised approximately £10 million (around $13 million) in a rece... |
| 10.09.2024 | NanoSyrinx Closes Approx. £10M Financing | NanoSyrinx, a Coventry, UK-based synthetic biology company, raised approx. £10M in funding.
The round was led by BGF, Octopus Ventures and M Ventures, with participation from new corporate investor, Eli Lilly and Company, and existing inves... |
| 10.09.2024 | NanoSyrinx closes c. £10 million GBP financing and appoints Dr. Edwin Moses as Chairman | Round co-led by BGF, Octopus Ventures and M Ventures, with support from new corporate investor, Eli Lilly and Company, and existing investors, IQ Capital and Meltwind
Appointment of Edwin Moses as Chairman to support the leadership team in ... |
| 26.08.2024 | Opna Bio Doses First Patient in Phase 1 Study in Multiple Myeloma with OPN-6602, an EP300/CBP Bromodomain Inhibitor | Appoints Axel Bolte, MBA, MSc, to Board Director and Stephanie Oestreich, PhD, MPA, to Board Observer
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–August 26, 2024–
Opna Bio announced that it has dosed the first patient with OPN-6602, a poten... |
| 23.05.2024 | Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement | SYDNEY, May 23, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) (Kazia or the company) received a letter on May 22, 2024 from Nasdaq notifying the Company that, while the Company has not regained compliance with the Minimum B... |
| 23.01.2024 | Ahead of Medicare drug price reform, pharma’s drug pricing has a Streisand effect | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with a look at some polarizing cancer data, a strange CEO transition, and the importanc... |
| 14.11.2023 | Autobahn Labs Announces Key Licensing Milestones in Alliances with Early University Partners | I’m thrilled to see our early partnerships bearing fruit. The two startups, in which we have already invested considerable effort and funding, benefit from exclusive licenses to key university IP.”
— Dr. Thomas Novak, Chief Scientific Offic... |
| 08.08.2023 | Autobahn Labs Appoints Chief Executive Officer | Brendan O'Leary - CEO, Autobahn Labs
Experienced Life Sciences Executive and Venture Capitalist Dr. Brendan O’Leary Joins Autobahn Labs as CEO
We are delighted to welcome Brendan O'Leary to Autobahn Labs. His experience, judgement, and forw... |
| 09.05.2023 | Autobahn Labs Announces Strategic Collaboration with the Salk Institute for Biological Studies | New Collaboration Adds to Autobahn Labs’ Transformative Biotech Incubator Model in California and the Northeast
The rigor and potential of research at Salk offers a solid foundation for breakthrough drug discoveries that will enable therapi... |
| 07.04.2023 | Cyber Attack on Evotec | HAMBURG, GERMANY / ACCESSWIRE / April 7, 2023 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN:DE 000 566480 9, WKN 566480, NASDAQ:EVO) announces that on 06 April, 2023 a cyber attack occurred on Evotec‘s IT systems. As a resu... |
| 13.02.2023 | Hamburg-based Evotec bags €150M loan from EIB to accelerate global access to therapeutics | Hamburg-based Evotec, a life sciences company, announced on Friday, February 10, that it has raised an unsecured loan facility of €150M from the European Investment Bank (EIB).
Evotec says it will use the funds to accelerate its R&D act... |
| 10.02.2023 | Evotec Receives € 150 m Loan from European Investment Bank | FINANCING FOR 3 CORE PILLARS: R&D ACTIVITIES, EQUITY INVESTMENTS AND CONSTRUCTION OF MANUFACTURING FACILITY DEDICATED TO BIOLOGICS, J.POD ® TOULOUSE, FRANCE (EU)
FOLLOW-ON TO THE EXISTING € 75 M LOAN FACILITY FROM 2017
UNSECURED LOAN FA... |
| 10.02.2023 | Evotec Receives € 150 m Loan from European Investment Bank | FINANCING FOR 3 CORE PILLARS: R&D ACTIVITIES, EQUITY INVESTMENTS AND CONSTRUCTION OF MANUFACTURING FACILITY DEDICATED TO BIOLOGICS, J.POD ® TOULOUSE, FRANCE (EU)
FOLLOW-ON TO THE EXISTING € 75 M LOAN FACILITY FROM 2017
UNSECURED LOAN FA... |
| 26.01.2023 | Evotec Announces Agreement with Janssen to Develop Immune-Based Therapies | STRATEGIC PARTNERSHIP LEVERAGES EVOTEC'S EXPERTISE & INTEGRATED PLATFORM FOR DISCOVERY AND DEVELOPMENT
HAMBURG, GERMANY / ACCESSWIRE / January 26, 2023 / Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) anno... |
| 03.11.2022 | Evotec Completes Acquisition of Central Glass Germany | AS EVOTEC DRUG SUBSTANCE (GERMANY) GMBH, THE ACQUISITION STRENGTHENS EVOTEC'S CLINICAL AND COMMERCIAL DRUG SUBSTANCE MANUFACTURING CAPACITY AND CAPABILITY ESPECIALLY FOR RARE DISEASES AND PRECISION THERAPEUTICS
HAMBURG, GERMANY / ACCESSWIRE... |
| 25.08.2022 | Evotec Expands Clinical and Commercial Drug Substance Manufacturing with Acquisition of Central Glass Germany | EXPANSION OF CGMP DRUG SUBSTANCE MANUFACTURING PLATFORM WILL CREATE A CLEAR PATH TO THE MARKET FOR RARE DISEASES AND PRECISION THERAPEUTICS
EVOTEC GAINS A FULLY OPERATIONAL EU GMP CERTIFIED FACILITY IN HALLE/WESTPHALIA ALONG WITH A HIGHLY S... |
| 22.06.2022 | Evotec SE Reports Results of Annual General Meeting 2022 | ALL AGENDA ITEMS ADOPTED WITH THE REQUIRED MAJORITY
CAMILLA MACAPILI LANGUILLE ELECTED AS NEW MEMBER OF THE SUPERVISORY BOARD; KASIM KUTAY RESIGNS FROM SUPERVISORY BOARD
AUTHORISED CAPITAL 2022 RESOLVED
REVISED REMUNERATION SYSTEM FOR MANAG... |
| 14.06.2022 | Evotec Enters a Drug Discovery Collaboration with Janssen | STRATEGIC PARTNERSHIP LEVERAGES EVOTEC'S PROPRIETARY PLATFORM CAPABILITIES IN THE FIELD OF PROTEIN HOMEOSTASIS
HAMBURG, GERMANY / ACCESSWIRE / June 14, 2022 / Evotec SE (FRA:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO) announced today t... |
| 10.05.2022 | Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation | 8-YEAR EXTENSION AND EXPANSION OF COLLABORATION TO DEVELOP PIPELINE OF MOLECULAR GLUE DEGRADERS
COLLABORATION LEVERAGES EVOTEC'S PROPRIETARY EVO PANOMICS AND EVO PANHUNTER PLATFORMS COVERING HIGH-PERFORMANCE MULTI-OMICS AND INTEGRATED AI/ML... |
| 10.05.2022 | Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership | HAMBURG, GERMANY / ACCESSWIRE / May 10, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces today that the Company has extended and expanded its partnership with Bristol Mye... |
| 04.05.2022 | Evotec SE to Announce Results for the First Quarter 2022 on 11 May 2022 | HAMBURG, GERMANY / ACCESSWIRE / May 4, 2022 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first quarter of 2022 on Wednesday, 11 May 2022.
The Company is... |
| 03.05.2022 | Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies | May 3, 2022 |
| 08.04.2022 | Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb | THE PROGRAMME DESIGNATION IS BASED ON AN ANTISENSE-BASED APPROACH WHICH TRIGGERS A US$ 16 M PAYMENT TO EVOTEC BY BRISTOL MYERS SQUIBB
EVOTEC SOURCES LNAPLUS(TM) ANTISENSE TECHNOLOGY THROUGH A STRATEGIC PARTNERSHIP WITH SECARNA PHARMACEUTICA... |
| 31.01.2022 | Evotec SE: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] | DGAP Preliminary announcement financial reports: Evotec SE / Preliminary announcement on the disclosure of financial statements
Evotec SE: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 ... |
| 31.01.2022 | Evotec SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements | DGAP Preliminary announcement financial reports: Evotec SE / Preliminary announcement on the disclosure of financial statements
Evotec SE: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
31.... |
| 18.01.2022 | Evotec and Lilly enter into drug discovery collaboration in metabolic diseases | DGAP-News: Evotec SE / Key word(s): Miscellaneous
Evotec and Lilly enter into drug discovery collaboration in metabolic diseases
18.01.2022 / 07:30
The issuer is solely responsible for the content of this announcement.
COLLABORATION LEVERAG... |
| 11.01.2022 | Evotec : expands neuroscience collaboration with Bristol Myers Squibb to include new targeted protein degradation approach | NEWS RELEASE, 11 JANUARY 2022
EVOTEC EXPANDS NEUROSCIENCE COLLABORATION WITH BRISTOL MYERS SQUIBB TO INCLUDE NEW TARGETED PROTEIN DEGRADATION APPROACH
EXPANSION LEVERAGES A PROPRIETARY EVOTEC PLATFORM IN THE FIELD OF TARGETED PROTEIN DEGRAD... |
| 11.01.2022 | Evotec expands neuroscience collaboration with Bristol Myers Squibb to include new targeted protein degradation approach | DGAP-News: Evotec SE / Key word(s): Miscellaneous
Evotec expands neuroscience collaboration with Bristol Myers Squibb to include new targeted protein degradation approach
11.01.2022 / 07:30
The issuer is solely responsible for the content o... |
| 04.01.2022 | Evotec receives EUR 7.5 m grant for development of COVID-19 therapeutic | Evotec SE (Frankfurt Stock Exchange - EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced that the Company has been selected by the German Federal Ministry of Education and Research ('BMBF') to receive a grant for the development o... |
| 03.01.2022 | Evotec : receives 7.5 m grant for development of COVID-19 therapeutic | NEWS RELEASE, 03 JANUARY 2022
EVOTEC RECEIVES € 7.5 M GRANT FOR DEVELOPMENT OF COVID-19 THERAPEUTIC
EVOTEC RECEIVES A € 7.5 M GRANT FROM THE GERMAN FEDERAL MINISTRY OF EDUCATION AND RESEARCH ("BMBF") FOR THE DEVELOPMENT OF A
THERA... |
| 03.01.2022 | Evotec receives ? 7.5 m grant for development of COVID-19 therapeutic | DGAP-News: Evotec SE / Key word(s): Miscellaneous
Evotec receives ? 7.5 m grant for development of COVID-19 therapeutic
03.01.2022 / 07:30
The issuer is solely responsible for the content of this announcement.
EVOTEC RECEIVES A ? 7.5 M GRAN... |
| 16.12.2021 | Evotec : receives US$ 18 m grant for women's health | NEWS RELEASE, 16 DECEMBER 2021
EVOTEC RECEIVES US$ 18 M GRANT FOR WOMEN'S HEALTH
GRANT WILL SUPPORT FULLY INTEGRATED DRUG DISCOVERY PROGRAMME FROM SCREENING TO PRE-CLINICAL DEVELOPMENT CANDIDATE
PROJECT LEVERAGES EVOTEC'S WOMEN'S HEALTH PLA... |
| 16.12.2021 | Evotec receives US$ 18 m grant for women's health | DGAP-News: Evotec SE / Key word(s): Miscellaneous
Evotec receives US$ 18 m grant for women's health
16.12.2021 / 07:30
The issuer is solely responsible for the content of this announcement.
GRANT WILL SUPPORT FULLY INTEGRATED DRUG DISCOVERY... |
| 16.11.2021 | Evotec : announces the exercise of the Greenshoe option | NEWS RELEASE, 16 NOVEMBER 2021
EVOTEC ANNOUNCES THE EXERCISE OF THE GREENSHOE OPTION
Hamburg, Germany, 16 November 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809;
NASDAQ: EVO) today announced that BofA Secur... |
| 11.11.2021 | Evotec SE reports results for the first nine months 2021 and provides corporate update | STRONG OPERATIONAL PERFORMANCE LEADS TO SIGNIFICANT REVENUE GROWTH
CO-OWNED PIPELINE GAINING MOMENTUM
J.POD® REDMOND (US) OPERATIONAL
SUCCESSFUL PUBLIC OFFERING AT NASDAQ (AFTER PERIOD-END)
GUIDANCE FOR FULL-YEAR 2021 CONFIRMED
WEBCAST AND ... |
| 11.11.2021 | Evotec SE reports results for the first nine months 2021 and provides corporate update | DGAP-News: Evotec SE / Key word(s): 9 Month figures
Evotec SE reports results for the first nine months 2021 and provides corporate update
11.11.2021 / 07:01
The issuer is solely responsible for the content of this announcement.
STRONG OPER... |
| 10.11.2021 | Evotec reaches programme designations in neuroscience collaboration with Bristol Myers Squibb | DGAP-News: Evotec SE / Key word(s): Miscellaneous
Evotec reaches programme designations in neuroscience collaboration with Bristol Myers Squibb
10.11.2021 / 07:30
The issuer is solely responsible for the content of this announcement.
THE DE... |
| 10.11.2021 | Evotec reaches programme designations in neuroscience collaboration with Bristol Myers Squibb | NEWS RELEASE, 10 NOVEMBER 2021
EVOTEC REACHES PROGRAMME DESIGNATIONS IN NEUROSCIENCE COLLABORATION WITH BRISTOL MYERS SQUIBB
THE DESIGNATION OF ADDITIONAL PROGRAMMES BY BRISTOL MYERS SQUIBB TRIGGERED PAYMENTS OF IN TOTAL US$ 40 M TO EVOTEC
... |
| 09.11.2021 | Evotec SE announces closing of public offering | NEWS RELEASE, 09 NOVEMBER 2021
EVOTEC ANNOUNCES CLOSING OF PUBLIC OFFERING
Hamburg, Germany, 09 November 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809;
NASDAQ: EVO) announced today the closing of its public... |
| 04.11.2021 | Evotec SE Announces Placement of its Public Offering of American Depositary Shares | Evotec SE Announces Placement of its Public Offering of American Depositary Shares
Hamburg, Germany, 3 November 2021:
Evotec SE's (Frankfurt Stock Exchange; EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) management board today decided - ... |
| 27.10.2021 | Evotec SE: Translational BRIDGE beLAB2122 in collaboration with Bristol Myers Squibb identifies first project | Evotec SE: Translational BRIDGE beLAB2122 in collaboration with Bristol Myers Squibb identifies first project
FIRST PROJECT ORIGINATES FROM THE GERMAN CANCER RESEARCH CENTER ("DKFZ") AND HEIDELBERG UNIVERSITY IN HEIDELBERG
beLAB21... |
| 27.10.2021 | Evotec announces first funded projects of translational BRIDGE beLAB1407 in collaboration with Bristol Myers Squibb | Evotec announces first funded projects of translational BRIDGE beLAB1407 in collaboration with Bristol Myers Squibb
FIRST TWO PROJECTS FROM THE UNIVERSITIES OF BIRMINGHAM AND EDINBURGH SELECTED
beLAB1407 IS A TRANSLATIONAL BRIDGE COLLABORAT... |
| 26.10.2021 | German drug developer Evotec seeks over $9 bln valuation in U.S. IPO | Oct 26 (Reuters) - Frankfurt-listed drug discovery and development company Evotec SE said on Tuesday it was seeking a valuation of about $9.2 billion in its initial public offering in the United States. (Reporting by Niket Nishant in Bengal... |
| 26.10.2021 | German biotech Evotec seeks over $9 bln valuation in U.S. IPO | Oct 26 (Reuters) - German biotech firm Evotec SE said on Tuesday it would seek a valuation of about $9.2 billion in its initial public offering in the United States.
The company has a market capitalization of $8.3 billion on the Frankfurt S... |
| 26.10.2021 | Evotec SE announces launch of public offering of American Depositary Shares | Evotec SE announces launch of public offering of American Depositary Shares
Hamburg, Germany, 26 October 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that it has commenced a public offerin... |
| 21.10.2021 | Growing together with partners | |
| 11.10.2021 | Strong Pipeline of Drugs for Treatment Of Psychotic Disorders Anticipated To Drive The Market Through 2028 | PALM BEACH, Fla., Oct. 11, 2021 /PRNewswire/ -- There is a high demand for more advanced products for the treatment and maintenance of severe mental disorders. Thus, pharmaceutical companies are investing a huge amount of money for novel dr... |
| 11.10.2021 | Strong Pipeline of Drugs for Treatment Of Psychotic Disorders Anticipated To Drive The Market Through 2028 | FinancialNewsMedia.com News Commentary
PALM BEACH, Fla., Oct. 11, 2021 /PRNewswire/ -- There is a high demand for more advanced products for the treatment and maintenance of severe mental disorders. Thus, pharmaceutical companies are invest... |
| 08.10.2021 | Evotec : expands neuroscience collaboration with Bristol Myers Squibb to include novel cell type | DGAP-News: Evotec SE / Key word(s): Miscellaneous
Evotec expands neuroscience collaboration with Bristol Myers Squibb to include novel cell type
08.10.2021 / 07:30
The issuer is solely responsible for the content of this announcement.
INCLU... |
| 08.10.2021 | Evotec : expands neuroscience collaboration with Bristol Myers Squibb to include novel cell type | Evotec expands neuroscience collaboration with Bristol Myers Squibb to include novel cell type
INCLUDES NEW CELL TYPES FOR STUDYING MOLECULAR DISEASE SIGNATURES FOR DISCOVERY OF DISEASE-MODIFYING THERAPIES FOR NEURODEGENERATIVE DISEASES
TRI... |
| 04.09.2021 | Abrupt FDA exits spark concern; Unpacking key concepts at gene therapy summit; 20 luminaries who reshaped R&D; and more | Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to... |
| 03.09.2021 | Ziopharm finds new CEO after six-month search; CFO transition at Lonza to take place in December | Kevin Boyle
Less than a year removed from a successful activist attack, Ziopharm Oncology appointed a new CEO this week. Taking the reins will be Kevin Boyle, who comes over after leading Kuur Therapeutics to a $185 milli... |
| 03.09.2021 | Sister to Juno's liso-cel, JW's relma-cel lands second-ever CAR-T approval in China | Juno may have stumbled its way to a distant third finish in the CD19 CAR-T race, but its joint venture in China is heading off to a thriving start.
JW Therapeutics, which took its name from co-founders Juno and WuXi AppTec, has sc... |
| 03.09.2021 | Bristol Myers licenses for Evotec molecule for $20M; FDA approves Impel's migraine nasal spray Trudhesa | Bristol Myers Squibb has exercised its option with Evotec for EVT8683, a small molecule created by the German biotech to target a specific “cellular stress response.”
The companies have obtained clearance to start human... |
| 02.09.2021 | Evotec : announces Bristol Myers Squibb opt-in of EVT8683 as the first programme from iPSC-based neurodegeneration collaboration | Evotec announces Bristol Myers Squibb opt-in of EVT8683 as the first programme from iPSC-based neurodegeneration collaboration
BRISTOL MYERS SQUIBB EXERCISES ITS OPTION TO ENTER INTO A GLOBAL LICENSE AGREEMENT FOR THE FIRST PROGRAMME FROM T... |
| 02.09.2021 | Evotec : partner Kazia Therapeutics announces full regulatory approval for Phase I study of EVT801 | Evotec partner Kazia Therapeutics announces full regulatory approval for Phase I study of EVT801
Sydney, Australia, 02 September 2021:
Evotec partner Kazia Therapeutics Limited ('Kazia', ASX: KZA; NASDAQ: KZIA) today announced that the plan... |
| 02.09.2021 | PRESS RELEASE : Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals and Evotec expand strategic partnership in the field of antisense drug discovery | DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Miscellaneous Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals and Evotec expand strategic partnership in the field of antisense drug discovery 2021-09-02... |
| 02.09.2021 | Evotec : announces Bristol Myers Squibb opt-in of EVT8683 as the first programme from iPSC-based neurodegeneration collaboration | DGAP-News: Evotec SE / Key word(s): Miscellaneous
Evotec announces Bristol Myers Squibb opt-in of EVT8683 as the first programme from iPSC-based neurodegeneration collaboration
02.09.2021 / 07:30
The issuer is solely responsible for the con... |
| 02.09.2021 | Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals and Evotec expand strategic partnership in the field of antisense drug discovery | DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Miscellaneous
Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals and Evotec expand strategic partnership in the field of antisense drug discovery
02.09.2021... |
| 02.09.2021 | Evotec : and Secarna Pharmaceuticals expand strategic partnership in the field of antisense drug discovery | Munich/Martinsried and Hamburg, Germany, 02 September 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Secarna Pharmaceuticals GmbH & Co. KG ('Secarna'), a biopharmaceutical company focusing on the di... |
| 02.09.2021 | Hot off of a $210M Series B, Umoja breaks ground in Colorado on CAR-T site | Boulder County, CO, is getting a new manufacturing facility, and it will come from a Seattle oncology company focused on CAR T-cell immunotherapies.
Umoja Biopharma broke ground on a new facility for in vivo immu... |
| 31.08.2021 | In a major blow to vaccine efforts, senior FDA leaders stepping down | A program touted by Novartis CEO Vas Narasimhan as a near-slam dunk has flopped a Phase IIb study, leading the Swiss biopharma to discontinue the trial altogether.
The candidate in question, iscalimab or CFZ533, proved less effective than s... |
| 31.08.2021 | In a major blow to vaccine efforts, senior FDA leaders stepping down | A private equity group has joined hands with a sovereign wealth fund out of Singapore to strike a deal to buy Swedish Orphan Biovitrum — a high-profile rare disease player better known as Sobi — for $8 billion and take the company private. ... |
| 31.08.2021 | In a major blow to vaccine efforts, senior FDA leaders stepping down | Two prominent House committees are digging deeper into the FDA’s cozy relationship with Biogen as it reviewed and approved its new Alzheimer’s drug Aduhelm.
While the committees were briefed by FDA on the situation in mid-July, the chairs a... |
| 12.08.2021 | Manufacturing issues hold back distribution of overdose injection; San Diego biotech triples footprint | In April, Pfizer was forced to stop production of the injectable opioid antidote naloxone, after a manufacturing issue. Now, a shortage has raised the alarm for advocates, who are saying the lack of access coupled with an all-time high of d... |
| 11.08.2021 | Evotec : Just - Evotec Biologics opens J.POD® 1 US in Redmond, Washington | Just - Evotec Biologics opens J.POD® 1 US in Redmond, Washington
J.POD® 1 US PROVIDES UNIQUELY FLEXIBLE CGMP MANUFACTURING OF KILOGRAMS TO METRIC TONS OF BIOLOGICS THERAPEUTICS
J.POD® FACILITY EXPANDS JUST - EVOTEC BIOLOGICS' CAPABILITIES I... |
| 11.08.2021 | Evotec : Just - Evotec Biologics opens J.POD 1 US in Redmond, Washington | DGAP-News: Evotec SE / Key word(s): Miscellaneous
Just - Evotec Biologics opens J.POD 1 US in Redmond, Washington
11.08.2021 / 07:30
The issuer is solely responsible for the content of this announcement.
J.POD(R) 1 US PROVIDES UNIQUELY FLEX... |
| 03.08.2021 | Evotec SE: Positive Phase IIb data for investigational P2X3 antagonist in patients with refractory chronic cough | Evotec SE: Positive Phase IIb data for investigational P2X3 antagonist in patients with refractory chronic cough
Hamburg, Germany, 03 August 2021:
Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480) announce... |
| 02.08.2021 | Evotec : Announces Confidential Submission of Draft Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission for a Proposed Offering of American Depositary Shares | Evotec SE Announces Confidential Submission of Draft Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission for a Proposed Offering of American Depositary Shares
Hamburg, Germany, 02 August 2021:
Evotec SE (Fran... |
| 29.07.2021 | Evotec : spin-off Topas Therapeutics extends Series B, raising total of 40 Million (~$48 Million) in this Round | Evotec spin-off Topas Therapeutics extends Series B, raising total of €40 Million (~$48 Million) in this Round
Funds to be used to obtain clinical proof of concept in two programs and to accelerate innovative pipeline focused on restoring i... |
| 29.07.2021 | Evotec : spin-off Topas Therapeutics extends Series B, raising total of 40 m (~ $ 48 m) in this Round | Funds to be used to obtain clinical proof of concept in two programs and to accelerate innovative pipeline focused on restoring immune tolerance to treat and potentially cure autoimmune diseases
Initial clinical data for lead program, TPM20... |
| 29.07.2021 | Evotec : spin-off Topas Therapeutics extends Series B, raising total of 40 m (~$ 48 m) in this round | Evotec spin-off Topas Therapeutics extends Series B, raising total of € 40 m (~$ 48 m) in this round
Funds to be used to obtain clinical proof of concept in two programs and to accelerate innovative pipeline focused on restoring immune tole... |
| 01.07.2021 | Evotec : creates long-term growth opportunities by initiating 'Campus Levi-Montalcini' in Verona | DGAP-News: Evotec SE / Key word(s): Miscellaneous
Evotec creates long-term growth opportunities by initiating 'Campus Levi-Montalcini' in Verona
01.07.2021 / 07:30
The issuer is solely responsible for the content of this announcement.
EVOTE... |
| 01.07.2021 | Evotec : creates long-term growth opportunities by initiating "Campus Levi-Montalcini" in Verona | Evotec creates long-term growth opportunities by initiating 'Campus Levi-Montalcini' in Verona
EVOTEC ACQUIRES THE VERONA SITE FROM GSK AND SECURES CAPACITY FOR LONG-TERM GROWTH
EMPLOYEES VOTE FOR SITE TO BE NAMED 'CAMPUS LEVI-MONTALCINI' I... |
| 15.06.2021 | EVOTEC SE
Evotec : launches 'PRROTECT', a pre-competitive initiative to be better prepared for future pandemics | DGAP-News: Evotec SE / Key word(s): Miscellaneous
Evotec launches 'PRROTECT', a pre-competitive initiative to be better prepared for future pandemics
15.06.2021 / 07:30
The issuer is solely responsible for the content of this announcement.
... |
| 15.06.2021 | EVOTEC SE
Evotec : launches “PRROTECT”, a pre-competitive initiative to be better prepared for future pandemics | Evotec launches 'PRROTECT', a pre-competitive initiative to be better prepared for future pandemics
INTEGRATED PLATFORM APPROACH TO RESPOND TO THE CHALLENGES OF PANDEMIC PREPAREDNESS, RAPID RESPONSE AND DELIVERABILITY
PRROTECT COMBINES FIRS... |
| 14.06.2021 | EVOTEC SE
Evotec : partners with CEBINA to launch Danube Labs, a partnership to develop cutting edge biotechnology projects sourced from Central and Eastern European Universities and Research Institu... | Vienna, Austria, 14 June 2021:
CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the launch of Danube Labs, a partnership with Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) to fast... |
| 07.06.2021 | EVOTEC SE
Evotec : Autobahn Labs incubator announces partnership with Cold Spring Harbor Laboratory to advance novel science to the clinic | Autobahn Labs incubator announces partnership with Cold Spring Harbor Laboratory to advance novel science to the clinic
Expansion to East Coast validates Autobahn Labs' novel incubator model
Palo Alto, CA, USA, 07 June 2021:
Autobahn Labs, ... |
